Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009930 | 0.91 | ITGB3 (0.34) | ITGB3ITGA2BCYSLTR1CYSLTR2GRM2 | |
| SCHEMBL2005638 | 0.90 | ITGB3 (0.38) | ITGB3ITGA2BCYSLTR1CYSLTR2GRM2 | |
| SCHEMBL2010502 | 0.89 | ITGB3 (0.39) | ITGB3ITGA2BCYSLTR1CYSLTR2GRM2 | |
| SCHEMBL2010862 | 0.86 | ITGB3 (0.35) | ITGB3ITGA2B | |
| SCHEMBL2010825 | 0.85 | PRMT5 (0.34) | ITGB3ITGA2BCYSLTR1CYSLTR2GRM2 | |
| SCHEMBL2013752 | 0.85 | ITGB3 (0.47) | ITGB3ITGA2B | |
| SCHEMBL2005506 | 0.82 | ITGB3 (0.42) | ITGB3ITGA2BCYSLTR1CYSLTR2GRM2 | |
| SCHEMBL2010110 | 0.82 | ITGB3 (0.48) | ITGB3ITGA2B | |
| SCHEMBL2011677 | 0.81 | PPARG (0.35) | ITGB3ITGA2BCYSLTR1CYSLTR2GRM2 | |
| SCHEMBL2008211 | 0.81 | AOC3 (0.35) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | ITGB3 169/4885ITGA2B 63/4885CYSLTR1 229/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | ITGB3 169/4885ITGA2B 63/4885CYSLTR1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.